Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
| Total | Transactions | Amount |
| Buys | 0 | $0 |
| Sells | 32 | $2,850,062 |
| Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
| 04 Oct 2024 17:29 | NTLA | Intellia Therapeutics Inc | DUBE MICHAEL P | VP, Chief Accounting Officer | 02 Oct 2024 | Sale | 2,012 | 19.01 | 38,248 | D |
| 03 Jul 2024 13:15 | NTLA | Intellia Therapeutics Inc | CLARK ELIANA | EVP, Chief Technical Officer | 01 Jul 2024 | Sale | 405 | 22.93 | 9,287 | D |
| 20 Jun 2024 17:00 | NTLA | Intellia Therapeutics Inc | VERWIEL FRANK | Director | 17 Jun 2024 | Sale | 1,505 | 25 | 37,625 | D |
| 05 Mar 2024 16:10 | NTLA | Intellia Therapeutics Inc | BASTA JAMES | EVP, General Counsel | 04 Mar 2024 | Sale | 2,297 | 32.99 | 75,778 | D |
| 05 Mar 2024 16:10 | NTLA | Intellia Therapeutics Inc | CLARK ELIANA | EVP, Chief Technical Officer | 04 Mar 2024 | Sale | 605 | 32.99 | 19,959 | D |
| 10 Jan 2024 16:15 | NTLA | Intellia Therapeutics Inc | SEPP-LORENZINO LAURA | EVP, Chief Scientific Officer | 08 Jan 2024 | Sale | 667 | 29.38 | 19,596 | D |
| 10 Jan 2024 16:15 | NTLA | Intellia Therapeutics Inc | SEPP-LORENZINO LAURA | EVP, Chief Scientific Officer | 08 Jan 2024 | Sale | 1,608 | 28.66 | 46,085 | D |
| 05 Jan 2024 16:51 | NTLA | Intellia Therapeutics Inc | LEONARD JOHN M | President and CEO | 03 Jan 2024 | Sale | 19,223 | 29.46 | 566,310 | D |
| 05 Jan 2024 16:50 | NTLA | Intellia Therapeutics Inc | LEBWOHL DAVID | EVP, Chief Medical Officer | 03 Jan 2024 | Sale | 5,843 | 29.46 | 172,135 | D |
| 05 Jan 2024 16:50 | NTLA | Intellia Therapeutics Inc | SEPP-LORENZINO LAURA | EVP, Chief Scientific Officer | 03 Jan 2024 | Sale | 5,532 | 29.46 | 162,973 | D |
| 05 Jan 2024 16:49 | NTLA | Intellia Therapeutics Inc | GODDARD GLENN | EVP, Chief Financial Officer | 03 Jan 2024 | Sale | 5,365 | 29.46 | 158,053 | D |
| 05 Jan 2024 16:46 | NTLA | Intellia Therapeutics Inc | HICKS DEREK | EVP, Chief Business Officer | 03 Jan 2024 | Sale | 3,877 | 29.46 | 114,216 | D |
| 05 Jan 2024 16:45 | NTLA | Intellia Therapeutics Inc | BASTA JAMES | EVP, General Counsel | 03 Jan 2024 | Sale | 3,805 | 29.46 | 112,095 | D |
| 05 Jan 2024 16:44 | NTLA | Intellia Therapeutics Inc | CLARK ELIANA | EVP, Chief Technical Officer | 03 Jan 2024 | Sale | 4,301 | 29.46 | 126,707 | D |
| 05 Jan 2024 16:44 | NTLA | Intellia Therapeutics Inc | CLARK ELIANA | EVP, Chief Technical Officer | 03 Jan 2024 | Sale | 307 | 30.12 | 9,247 | D |
| 02 Nov 2023 16:42 | NTLA | Intellia Therapeutics Inc | BHANJI MUNA | Director | 31 Oct 2023 | Sale | 265 | 23.9 | 6,334 | D |
| 02 Aug 2023 17:19 | NTLA | Intellia Therapeutics Inc | BHANJI MUNA | Director | 31 Jul 2023 | Sale | 265 | 42.33 | 11,217 | D |
| 10 Jul 2023 17:21 | NTLA | Intellia Therapeutics Inc | BHANJI MUNA | Director | 06 Jul 2023 | Sale | 1,867 | 39.3 | 73,373 | D |
| 06 Jul 2023 15:34 | NTLA | Intellia Therapeutics Inc | CLARK ELIANA | EVP, Chief Technical Officer | 03 Jul 2023 | Sale | 360 | 40.51 | 14,584 | D |
| 22 Jun 2023 17:52 | NTLA | Intellia Therapeutics Inc | CLARK ELIANA | EVP, Chief Technical Officer | 20 Jun 2023 | Sale | 5,000 | 45 | 225,000 | D |
| 03 Mar 2023 17:10 | NTLA | Intellia Therapeutics Inc | BASTA JAMES | EVP, General Counsel | 02 Mar 2023 | Sale | 1,088 | 43.88 | 47,741 | D |
| 06 Jan 2023 17:39 | NTLA | Intellia Therapeutics Inc | SEPP-LORENZINO LAURA | EVP, Chief Scientific Officer | 05 Jan 2023 | Sale | 689 | 39.1 | 26,940 | D |
| 06 Jan 2023 17:39 | NTLA | Intellia Therapeutics Inc | SEPP-LORENZINO LAURA | EVP, Chief Scientific Officer | 05 Jan 2023 | Sale | 1,641 | 38.22 | 62,719 | D |
| 06 Jan 2023 17:39 | NTLA | Intellia Therapeutics Inc | SEPP-LORENZINO LAURA | EVP, Chief Scientific Officer | 04 Jan 2023 | Sale | 2,508 | 37.21 | 93,323 | D |
| 06 Jan 2023 17:32 | NTLA | Intellia Therapeutics Inc | LEONARD JOHN M | President and CEO | 04 Jan 2023 | Sale | 6,673 | 37.21 | 248,302 | D |
| 06 Jan 2023 17:29 | NTLA | Intellia Therapeutics Inc | HICKS DEREK | EVP, Chief Business Officer | 04 Jan 2023 | Sale | 1,812 | 37.21 | 67,425 | D |
| 06 Jan 2023 17:26 | NTLA | Intellia Therapeutics Inc | LEBWOHL DAVID | EVP, Chief Medical Officer | 04 Jan 2023 | Sale | 2,574 | 37.21 | 95,779 | D |
| 06 Jan 2023 17:23 | NTLA | Intellia Therapeutics Inc | GODDARD GLENN | EVP, Chief Financial Officer | 04 Jan 2023 | Sale | 2,427 | 37.21 | 90,309 | D |
| 06 Jan 2023 17:21 | NTLA | Intellia Therapeutics Inc | CLARK ELIANA | EVP, Chief Technical Officer | 04 Jan 2023 | Sale | 1,692 | 37.21 | 62,959 | D |
| 06 Jan 2023 17:21 | NTLA | Intellia Therapeutics Inc | CLARK ELIANA | EVP, Chief Technical Officer | 03 Jan 2023 | Sale | 231 | 34.48 | 7,965 | D |
| 06 Jan 2023 17:21 | NTLA | Intellia Therapeutics Inc | CLARK ELIANA | EVP, Chief Technical Officer | 01 Jul 2022 | Sale | 105 | 51.74 | 5,433 | D |
| 06 Jan 2023 17:19 | NTLA | Intellia Therapeutics Inc | BASTA JAMES | EVP, General Counsel | 04 Jan 2023 | Sale | 1,138 | 37.21 | 42,345 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)